

PFAS Biomonitoring to Support Exposure Reduction Efforts - Next Steps

Discussion Questions

Biomonitoring California Scientific Guidance Panel Meeting
November 8, 2021



- Referring to the opportunities for further analyses of Biomonitoring California's existing datasets on perfluoroalkyl and polyfluoroalkyl substances (PFASs) that were highlighted in [Kathleen Attfield's talk](#):
 - Which are the most promising for illuminating PFAS trends in CA?
 - What types of analyses would you recommend to further understand the sources of racial disparities observed in the datasets?

- When examining PFAS data for pregnant women from the [MAMAS](#) project, what potential limitations and confounders should we be concerned with?
 - How should these limitations and confounders inform the design of future sample selection from the GDSP (Genetic Disease Screening Program) Biobank?

- With regard to identifying key PFAS exposure sources in biomonitoring studies, which will help inform exposure reduction efforts:
 - What advice do you have on designing PFAS exposure questionnaires? What limitations of questionnaires are of concern for evaluating PFAS exposures?
 - What other approaches would you suggest to help evaluate PFAS exposure sources in our studies?

- Do you have any other input on next steps for Biomonitoring California to support PFAS exposure reduction efforts?